Morocco Pharmaceuticals & Healthcare Report

Published 24 March 2015

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Morocco Pharmaceuticals & Healthcare Report

BMI View: A new wave of drug price cuts in Morocco and the implementation of the final stage of its universal healthcare coverage programme will see an improvement in the population's access to medicines. While increasing access to medicines is positive for drugmakers, we highlight that the Moroccan pharmaceutical market will become increasingly challenging for innovative drugmakers due to the lack of clarity regarding further medicine price cuts and the increasing market share of generic medicines.

Headline Expenditure Projections

  • Pharmaceuticals: MAD10.63bn (USD1.13bn) in 2014 to MAD11.33bn (USD1.21bn) in 2015; +6.6% in local currency terms and +7.4% in US dollar terms.

  • Healthcare: MAD62.77bn (USD6.67bn) in 2014 to MAD67.97bn (USD7.28bn) in 2015; +8.3% in local currency terms and +9.1% in US dollar terms.

Risk/Reward Index

In our latest proprietary Pharmaceutical Risk/Reward Index table, Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 15th in the region, out of the 31 countries assessed, with a score of 41.8 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

February 2015

  • Indian pharmaceutical company Cipla's wholly owned UK subsidiary, Cipla EU, has signed a joint venture agreement with the company's existing Moroccan business partners Cooper Pharma and The Pharmaceutical Institute (PHI). Under the terms of the agreement, Cipla EU will hold a 60% stake in the venture, while Cooper Pharma and PHI will collectively own the remaining 40% stake. Cipla EU is expected to invest USD15mn in cash into the joint venture, which will be geared towards respiratory and neurology products and will also be used in establishing a production unit in Morocco....

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
21
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
25
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2012-2018)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2012-2018)
29
Other Healthcare Data
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Table: VARIOUS COUNTRIES - REAL GDP GROWTH, %
33
Industry Risk Reward Ratings
42
Middle East & Africa Risk/Reward Index
42
Morocco Risk/ Reward Ratings
49
Rewards
49
Risks
50
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Healthcare Sector
56
Healthcare Insurance
59
Recent Health Insurance Developments
62
Research & Development
65
Clinical Trials
66
Regulatory Development
67
Intellectual Property Regime
68
Pricing Regime
68
Reimbursement Regime
70
Competitive Landscape
73
Pharmaceutical Industry
73
Table: Morocco's Select Pharmaceutical Industry Indicators
73
Table: Members Of MIS, 2011
74
Table: Members Of AMIP, 2011
75
Domestic Pharmaceutical sector
75
Foreign Pharmaceutical Companies
76
Pharmaceutical Wholesale
78
Pharmaceutical Retail
79
Company Profile
81
Sothema
81
Laprophan
84
Promopharm
87
Sanofi
89
Pfizer
93
GlaxoSmithKline
96
Ranbaxy
98
Demographic Forecast
100
Table: Morocco's Population By Age Group, 1990-2020 ('000)
101
Table: Morocco's Population By Age Group, 1990-2020 (% of total)
102
Table: Morocco's Key Population Ratios, 1990-2020
103
Table: Morocco's Rural And Urban Population, 1990-2020
103
Glossary
104
Methodology
106
Pharmaceutical Expenditure Forecast Model
106
Healthcare Expenditure Forecast Model
106
Notes On Methodology
107
Risk/Reward Ratings Methodology
108
Ratings Overview
109
Table: Pharmaceutical Risk/Reward Ratings Indicators
109
Indicator Weightings
110

The Morocco Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Morocco pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Morocco, to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc